All Episodes
Mendelspod Podcast — 546 episodes
Solexa Co-Inventor Shankar Balasubramanian on Six-Base Sequencing and What's Next in Genomics
The Next Frontier in Biology: Physics? Erdinc Sezgin of the Karolinska Institute
The Case for a 6-Base Genome with Peter Fromen, CEO of Biomodal
The Eligible But Under-Tested: Genomic Medicine in 2026 with Damon Hostin, Illumina
Spatial Transcriptomics Is Changing How We Do Biology: Fei Chen, The Broad Institute
Beyond GLP-1: Why Peptides Are Back at the Center of Drug Discovery with Charlie Johannes and Tomi Sawyer
From the Archives: Inventor Mark Kokoris Debuts Roche’s New SBX Sequencer
Why Do Some Animals Live Ten Times Longer? Pursuing the Science of Aging with Steve Austad
MRD Testing: From Residual Disease to Real Decisions with Chris Hourigan and Gary Pestano
Early vs Late Recurrence: How Multimodal AI Is Changing Breast Cancer Prognosis with George Sledge, Caris Life Sciences
The Dark Genome with Author Sudhakaran Prabakaran
Illumina's New Mapped Read Technology Provides Insights into Rare Disease: Stephen Kingsmore, Olivia Kim-McManus and Ali Crawford
CareDx’s Second Act with CEO John Hanna
Inside GP2: Building a Global Genetic Map of Parkinson’s with Andrew Singleton and Ignacio Mata
A Simple Sponge, a Big Shift in Cell Therapy with Yev Brudno, UNC
How Cellanome Is Changing the Way We Study Cell Function with Matthew Spitzer and Pier Federico Gherardini
From Hereditary Risk to Residual Disease: Natera’s Integrated Vision for Precision Oncology with Adam ElNaggar, MD
The Rise of Geroscience with Alan Landay and Tom Blackwell, UTMB
Unlocking the RNA Revolution: How Self-Replicating RNA Could Transform Vaccines and Therapeutics with Andrew Geall, Replicate Bioscience
From Targets to Hits: The Emerging AI Ecosystem in Drug Discovery with Aqib Hasnain, Mithrl and Cheng Hu, Technetium Therapeutics
Most Popular Show of 2025: How Certis Is Rewriting Cancer Models with CEO Peter Ellman
Building the Front-End for Every Sequencer with Volta Labs CEO Udayan Umapathi
A New Foundational Platform for Biology: Cellanome’s Debut with CEO Omead Ostadan
The Best of Times, the Worst of Times: Former NHGRI Director Eric Green on a Shaken NIH and Surging Genomic Science
From the Archives: Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz
Petter Brodin of Karolinska: How Spatial Interactomics Could Transform Autoimmune Therapy
From GWAS to EWAS: Chirag Patel and and Gary Miller on the Rise of Exposomics
Agilent Partners with PacBio to Speed Adoption of Long Reads into Diagnostic Testing
How AI Is Doing Science with Vivek Adarsh, CEO of Mithrl
Inventor Mark Kokoris on Roche’s New Sequencing by Expansion
From Brewing Sake to Brewing Science: Takara Bio’s Bold New Chapter with CSO Andrew Farmer
How Pathologists Can Lead in Precision Medicine with David Braxton
From DNA to Proteins: Illumina Makes Its Proteomics Play - with Krishna Morampudi
Theranos Had the Vision. Truvian Has the Execution. Our Chat with CEO Jay Srinivasan
Physicians Don't Want a Laundry List of Genes says Premal Shah, CEO of Myome
The Customer Case for iconPCR with Stefan Green and Yann Jouvenot
Alex Dickinson on Long Read Sequencing, Multi Omics, and the Next Frontier in Genomics
Rapid Answers for Rare Disease: Katherine Stueland on GeneDx’s Mission
Moran Snir's Vision for Making Genomic Care Routine across the U.S.
How Certis Is Rewriting Cancer Models with CEO Peter Ellman
Myriad’s Next Chapter: New CEO Sam Raha on Growth, AI, and MRD Testing
Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz
Bodour Salhia and Danielle Goldberg: Rethinking Cancer Research with Illumina's 5-Base Solution
Reinventing PCR: Pranav Patel, N6 Tec
Making Whole Genome Sequencing the Universal Genetic Test - with David Ledbetter, Pediatric Rare Disease Institute, FSU
Remembering Atul Butte with Marina Sirota, Chirag Patel and Mike Snyder
The Age of Digital Pathology with Andy Beck, PathAI
What’s New for Regulatory Informatics in the Age of AI? Not Much—And That’s the Point with Raju Rayavarapu of DNAnexus
From Illumina to Advocacy: Mike Kreitzinger on the Future of Clinical Genomics
Amplifying the Expert: Jing Gao on Illumina's Connected Insights
The End of Animal Testing? Vivodyne Scales Human Tissue with CEO Andrei Georgescu
How Liquid Biopsy Is Becoming Standard of Care with Rita Shaknovich, CMO, Agilent
Tracking GMOs in the Gene Editing Era: Frédéric Debode on the Science of GMO Detection
From Discovery to Translation: Bruker's Bold New Play in Spatial with Joe Beechem and Oliver Braubach
Tagomics Wins NHS Grant, Unveils De-Methylation Platform for Early Cancer Testing with Rob Neely, CSO
From Paris to the Pentagon: Sophie Peresson Maps Biosecurity’s New Landscape
From Mitochondria to Protein Degradation: Mike Kiebish on BPGbio’s "Biology First" Vision
The Grammar of RNA: Gavin Knott on Gene Editing and Structural Biology in the Age of AI
The Third Way: Christian Schafmeister’s Spiroligomer Revolution
Can Math and AI Replace Some Biology in Drug Discovery? with Aridni Shah, Immunito AI
$10 Genome, $8 Coffee: Rethinking the Economics of Life Science Tools with Stephane Budel, DeciBio
Quantum Scale: A New Era for Single-Cell Analysis with Giovanna Prout
Building Intuition at the Nanoscale: Steve McCloskey of Nanome on the VR Future of Science
Beyond the $100 Genome--the Everyday Sequencing Revolution You Missed: Mark Budde, Plasmidsaurus
What Next for LDTs? A Conversation with Sarah Overton of Velsera
AI’s Quiet Revolution in the Pharma Supply Chain with Chris Petersen, Scientist.com
We've Been Misclassifying Childhood AML for Years: Jeffery Klco, St. Jude's
Aaron Viny: A 21-Year Leukemia Survivor on the Frontlines of Epigenetic Cancer Research
Toward Disease Sub-typing with Ben Busby, DNAnexus
Synthetic Biology Ready for Its ChatGPT Moment: A Preview of SynBioBeta 2025 with John Cumbers
Beyond the Parts List: Chris Mason and Simon Fredriksson on Mapping the Immune System in Space and Cancer with Cell Surface Proteomics
DNA Is Still Where It's At: Christian Henry, CEO of PacBio, on Watershed Year in 2024
A New Sequencing Technology Has Entered the World: Keith Robison Reviews AGBT and New Tech in our Annual Sequencing--er, Multi-Omics Show
Unlocking the Future of Forensic Genetics with Mirna Ghemrawi
Public Science in Peril: Hank Greely of Stanford on Funding, Fishing, and the Fight for Knowledge
Breaking the ‘Undruggable’ Barrier with AI and Synthetic Biology: Eswar Iyer, CEO of Aikium
"They're not cutting a branch. They're cutting the whole tree." Laura Hercher Defends DEI in Genomic Research and Medicine
Early Detection for Lung Cancer with Susan Tousi, DELFI Diagnostics
Big RNA with Brendan Frey of Deep Genomics
Genome Informatics in the Age of AI With Ben Busby, DNAnexus
AI & the Future of Genetic Testing: Ezra Cohen, CMO of Tempus
PredxBio and the Promise of Spatially Intelligent Biology
Surprise: Our Most Popular Show of 2024 Was on Genomic AI
New Startup Launches Epigenetic Screening: Mohamad Takwa, CEO, Epigenica
AI Powered Multiomics: Joachim Schmid on Data Analysis at Illumina
Renowned GI Oncologist Discusses MRD Testing and the Future of Cancer Detection
Precision Medicine Then and Now: We Talk with the Retiring President of the Personalized Medicine Coalition, Ed Abrahams
MicroRNA: A New Era in Biomarker Discovery with Tim Williams and Paola Ulivi
Somatic Genomics: A Revolution in Biology with Jacob Rubens
Exploring the Future of Single Cell Technology with Mauro Muraro, CEO, Single Cell Discoveries
Grail and Verily Alum on Billion Dollar Startup Bringing AI to Drug Development: A Discussion with Vik Bajaj
Singular Genomics Introduces a Dual-Purpose Platform Capable of Both NGS and Spatial Multiomics: Drew Spaventa, CEO & Founder
The Evolving Future of Genetic Counseling with Ellen Matloff, CEO, MyGeneCounsel
As Sequencing Continues to Scale, Volta Labs Improves Sample Prep: Udayan Umapathi, CEO
What’s Next for Large-Scale Proteomics? With Chris Whelan, Janssen
Will this At-Home Blood Collection Device Transform Medicine? Ben Casavant, Tasso
Geneticist Kevin Mitchell Attempts to Naturalize Free Will in New Book
ctDNA Testing Could Lead to New Ways of Staging Cancer Patients, Says Ben Weinberg, MedStar Georgetown
14th Season Opener: Michael Levin on ‘The New Biology’
The Success of ctDNA Testing in Colorectal Cancer: Adham Jurdi, Natera
Henrik Zetterberg on the Current Excitement Around Alzheimer’s Research
The Reboot of Consumer Genomics? with Kian Sadeghi, Nucleus Genomics
From Geospatial to Biospatial: Avi Veidman of Nucleai
New Proteomics Technology Brings Unprecedented Sensitivity and Scale: Yuling Luo, CEO, Alamar Bio
Diagnostic Trends in 2024 with Mara Aspinall, Illumina Ventures
The Actionable Epigenome with Bret Barnes, Illumina
Not All Prenatal Screens Are the Same: Jennifer Hoskovec, Billion to One
Harvard's Marc Lipsitch on the New White House Policy Regulating Risky Pathogen Research
Liquid Biopsy Goes Beyond Cancer: Diana Abdueva and Maggie Louie, Aqtual
Cell Therapy Will Transform Medicine as We Know It, Says Jason Bock, CTMC
Two Industry Leaders on Dealing with the Growing Complexity of Genomic Cancer Data
Single Cell Spatial Proteomics with Filip Karlsson, Pixelgen
The Precision Medicine Optimist: Damon Hostin, Illumina
An Ethics First Approach to Genetic Research and Drug Development with Sarah LeBaron von Baeyer
How Do You Train Genomics AI? On Natural Selection Itself, Says VP of Illumina’s AI Lab, Kyle Farh
The Pre-Symptomatic Space with Patrick Short, Sano Genetics
Systemwide Implementation of Precision Medicine at UCHealth with David Kao
Is this New Tech a Game Changer for Spatial Biology?
Synthetic Biology in 2024 with John Cumbers
Illumina Scales Variant Calling and Genome Interpretation to Improve Gap in Genetic Testing with Sam Strom
The Renaissance in DNA Synthesis Continues: Cosimo Ducani, CEO, Moligo
Jennifer Wipf of Ginkgo Bioworks on RNA Therapeutics and Cell Therapy
Precision Medicine for Dogs: Christina Lopes, OneHealth
Taking Gene Therapy to the Next Level: Rahul Kakkar of Tome
Christian Henry of PacBio on Long Reads at Scale, Next Moves
Robert Michel, Editor at The Dark Report, on Gap in Genetic Testing
Turning to Next Gen Proteomics for Novel Biomarkers: Jon Brudvig and Bruce Wilcox
What Have We Learned from the Brain Map Project So Far? with Tom Nowakowski, UCSF
Quality Healthcare Should Not Depend on Which Book Club You Attend, Karen Tumulty of the Washington Post
Real Probiotics: Colleen Cutcliffe, CEO, Pendulum Therapeutics
Todd Druley of Mission Bio on Single Cell Multi-Omics
Kevin Davies on Gene Therapy in 2023
History and State of Proteomics 2023 with John Yates
New Philosophy of Biology Series on PBS: A Preview with Host Robert Lawrence Kuhn
Mapping the Meta Proteome: John Shon, CTO, Serimmune
Supercharged Killer Cells Effective Against Alzheimer’s: Paul Song, CEO, NKGen Biotech
Chris Hall and Rich Chen of Personalis on Next Gen MRD Testing
State of Sequencing 2023: Shawn Baker and Keith Robison
Newborn Sequencing 2023 Part II: What Evidence Is Enough?
Lincoln Nadauld on the State of Precision Medicine in 2023
Nothing Is "Undruggable:" Alex Federation, CEO, Talus Bio
Mass Spec Advances in a New Age of Proteomics: Rosy Lee, Thermo Fisher Scientific
This Is Very Cool: Treating Cancer with Sound
The Future of Clinical Proteomics with Jenny Van Eyk and Daniel Hornburg
Elinor Karlsson on Darwin’s Ark
Long DNA for Difficult Applications: Dan Lin-Arlow, CEO, Ansa Biotech
Next Gen CRISPR Therapies with Trevor Martin, CEO of Mammoth Biosciences
13th Season Opener: Mike Snyder on Microsampling and Multi-Omic Profiling
Gene Patent Decision at 10 Years, State of Genetic Testing with Ellen Matloff, My Gene Counsel
Proteomics Bigger than Genomics, It’s Just Taking Time, Says Jeff Hawkins, CEO, Quantum-SI
Biden, AI, and DeSci: John Cumbers Previews SynBioBeta 2023
Proteomics Today Where Genomics Was in the 80s: Margaret Donovan and Asim Siddiqui of Seer on Landmark Study
Is This New Platform an Answer to the Reproducibility Crisis? with Guy Rohkin
Elegen Pioneers Long DNA Subindustry with CEO Matt Hill
Nevermind the $200 Genome, Element CEO Molly He Says Core Chemistry Capable of Much More
3D Genomics Solves Cancer Case Where Sequencing Came Up Short: Anthony Schmitt, Arima Genomics
New Spatial Company Maps Cell Surface Proteome without Imaging
John Greally on His Latest Review of Epigenomics
President of ASHG on Eugenics Apology, Diversity Initiative
23andMe Launches New Personalized Healthcare Initiative with Amy Sturm
Converting Digital to Biological: John Gill, Telesis Bio
50% Not Tested: Precision Oncology with Jerome Madison, Invitae
Paul Freemont on Synthetic Biology in the UK
The Bioengineered Hangover Cure: Changing the Conversation around GMOs with Zack Abbott of ZBiotics
Lance Baldo of Freenome on their Approach to Early Cancer Detection
Mara Aspinall on COVID
Terry Lo of Vizgen on Spatial Genomics
Proteomics at Scale Empowers Genomics in New Ways: Dale Yuzuki, Olink
A New Tool in the Genomics Kit with Ivan Liachko of Phase Genomics
Paul Kruszka of GeneDx/Sema4 on Groundbreaking Newborn Sequencing Study
Is PGx Having a Moment? Kristine Ashcraft, Invitae
Christian Henry on Revio, Onso and the New Vision at PacBio
The Revolution in Single Molecule Sequencing Continues: Vijay Ramani, UCSF
Will Hwang of Mass General on Discovery of Novel Pancreatic Cancer Cell Subtype
Going Beyond Time Barriers: Arutha Kulasinghe on the Power of New Spatial Biology Tools
Invitae’s Data Manager, Farid Vij, on New Genome Management Platform
Satellite Bio out with a New Tissue Based Approach to Regenerative Medicine
We Have to Get Sequencing Back to Moore’s Law: Gilad Almogy, Ultima Genomics
RNA Therapeutics: A New Paradigm for Drug Development? Tim Mercer, BASE Lab, U of Queensland
The System is Working. We Need More Engagement, Says ClinVar Champion Heidi Rehm of Mass General in Her Update on the State of Genomic Medicine in 2022
The Promise of Exosomes Now Realized, Says Paul Billings, CEO, Biological Dynamics
Lee Cronin on Origin of Life, Genomics, Aliens and More
Eric Green on the Future of the NHGRI
5-Base Sequencing: Jonas Korlach and Tomi Pastinen
More Cancer Patients Die from Infections than Cancer, Says Alec Ford, CEO of Karius
Some of the Lowest Hanging Fruits in Precision Medicine: Michelle Whirl-Carrillo on Pharmacogenomics
John Nelson of GE Research Talks Vaccines on Demand, Enzymatic Synthesis, and the Era of Writing DNA
A New Generation Comfortable Doing a Thousand Things at a Time Is Reinventing Life Science Says Joe Beechem of NanoString
Enabling a New Age of Unbiased Proteomics Discovery: Omid Farokhzad, Seer Inc.
The Rise of MRD Testing and the Field of Fragmentomics with Sugganth Daniel, Invitae
The Invention of Enzymatic DNA Synthesis with Sylvain Gariel, DNA Script
Akoya Biosciences Launches New Integrated Spatial Platform: Our First Interview with CEO Brian McKelligon
Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity
Twist Bioscience: A New Kind of DNA Synthesis Company
Going High Resolution with 10X Genomics: Michael Schnall-Levin
George Church and Ben Lamm on the Launch of Colossal Biosciences
We Might Be the Comeback Kids of the Universe: Chris Mason on His Plan for the Next 500 Years
Invitae and PacBio CEOs Share Details of Clinical Sequencing Partnership
Building on the Knowledge Base of Developer Community, LuminexPLORE Lab Offers Custom Insights: Jackie Surls, Director
DNA Script Takes DNA Synthesis Back to the Bench with Enzymatic Tech: Thomas Ybert, CEO
Tumor Evolution in Context with Christina Curtis
The History of mRNA Vaccines with Elie Dolgin
Hundreds of Thousands of Biological Molecules Undiscovered in Plant Chemical Space Says Founder of New Drug Discovery Company
Quantitative Pathology with David Rimm, Yale
The State of Comprehensive Genomic Profiling at One of America’s Largest Health Systems with Carlo Bifulco
Inside the World of Genome Engineering at Amyris with Kirsten Benjamin, VP of R&D
Clinical Genetics 2021 Highlights: Laura Hercher, Host of the Beagle Landed Podcast
A New Way to Phenotype Life: Chris Mason Talks Spatial Biology, His New Book
The Impact of Spatial Technology on Childhood Cancers with David Steffin, Texas Children's
Robert Green: Newborn Sequencing Is the Goal Here in the U.S.
The Studies Are In—Optical Mapping Can Replace Traditional Cytogenetics Tests
Amy Sturm of Geisinger on FH Testing and New Implementation Science
Out of the Reductionist Trap: Brad Gray of NanoString on Spatial Biology
Precision Oncology at the Community Level with Lee Schwartzberg
Daniel Kraft on the Digitome and COVID
Orchid Health Is 1st in the World to Offer Whole Genome Couple's Report
PacBio and Labcorp Team Up on a Global Pan-Pathogen Surveillance Network
Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix
A Liquid Biopsy Technology that Doesn't Degrade the Sample: Raj Krishnan of Biological Dynamics
The Future of Big Biology: Bionano at AGBT
Playing Catch Up--Viral Surveillance in the U.S. with Will Lee of Helix
The Coronavirus, A Year On with Carl Zimmer
Spatial Biology Enables The Cancer Immunome Project
The CRISPR Saga with Kevin Davies
PacBio’s Never Been Stronger: New CEO, Christian Henry, Shares His Vision
Keith Robison on the State of Sequencing: 2020 Edition
Halloween with Nathan and Laura: The Spooky and Creepy of Genomics
When and Why Whole Genome Sequencing Should Be Standard of Care: Stephen Kingsmore of Rady Children’s
Limited Genetic Diversity Affects Us All
Genomics England Making Significant Strides in System Built on Trust in NHS
September 2020 Review with Nathan and Laura: Vaccine Choice, Dwarfism, Research Volunteerism
Bob Nussbaum on the State of Genetic Testing: 2020 Edition
SynBioBeta 2020 with John Cumbers
Mapping Intracellular Context: Garry Nolan on Spatial Biology
August 2020 Review: Radical Shift on LDT Policy, First Pan-Cancer Liquid Biopsies, and New Alzheimer’s Test
Using CRISPR Genome Editing Tools, Willow Biosciences out with First Synthetic Cannabinoid
The Pros and Cons of Expanded Carrier Screening with Mary Norton, UCSF
Is This A Unique Time for Science? We Ask Sci-fi Writer Kim Stanley Robinson
May 2020 with Nathan and Laura: Vaccine News, Notre Dame Argument, COVID Genetic Targets
Matt Loose on "Read Until" or Adaptive Sequencing
The Current State of Coronavirus Vaccines with Jeff Stein, Cidara Therapeutics
April 2020 Review with Nathan and Laura: Ioannidis Scandal, Antibody Testing, Ethics Questions
Lab Director Speaks to the Challenges of COVID-19 Testing: Elaine Lyon, HudsonAlpha
FDA in the Time of Coronavirus: Understanding the New VALID Act with Turna Ray, GenomeWeb
March 2020 Review with Nathan & Laura: Corona Gets Personal, Where Are the Tests?, the VALID Act, Some non-Corona Science
90% Go Undiagnosed, Says Geisinger’s Amy Sturm of FH Patients
Lisa Alderson on Her Telegenetics Firm, Genome Medical, Also Speaks to the DTC Downturn
February 2020 Review with Nathan and Laura: Coronavirus, Medicare for All, and Live from AGBT
Pouria Sanae on the DTC Slowdown and His New Precision Health Testing Platform
January 2020 Review: Genetic Counselors vs ACMG, 23andMe Layoffs, Privacy
End-of-Decade Review, What's Next? with Nathan and Laura
Ewan Birney on Race, UK Genomics
November 2019 with Nathan and Laura: Happy Birthday CRISPR Babies, 23andMe for Embryo Selection, and Golden Rice, Almost
Learning from the Field's Mistakes, Ancestry.com Rolls out Physician Ordered Health Testing
The Gene Edited Babies Saga - A Year Later with Hank Greely
Improving Quantitative Evidence for Genetic Tests: Carlos Araya, Invitae
The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO
October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG
Should We Increase Panel Testing for All Breast Cancer Patients?
Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution
Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019
Karen Miga on the Next Era of Genomics
September 2019 Review with Nathan and Laura: Same-Sex Genetics, Mosquitos, and Another DTC Scandal
We Can See Tumor Heterogeneity. Now What? We Ask Cathy Smith, UCSF
Hallelujah! A Universal Flu Preventative and Therapy with Jeff Stein, Cidara
'The Movement:' John Cumbers Previews the Rapidly Growing SynBioBeta 2019
Anya Prince on Our Current Vulnerability to Genetic Discrimination
Do Long Reads Hold Answers for Alzheimer’s? with Mark Ebbert, Mayo
With Nanopore Sensing Beyond Sequencing, Ontera Takes 'Lab' to the Field
Mark Chaisson on Two New Structural Variation Papers
Early Cancer Detection: Is This Company Ahead of Grail?
June 2019 Review with Nathan and Laura: Gene Patents, Grail, Dr. Lynch
Should Genomic Screening Be Standard of Care? with Adam Buchanan, Geisinger
May 2019 Review with Nathan and Laura: Gene Therapies, DTC Shifts, Gender and Sports
Toward the Human Pan Genome with Adam Phillippy, NHGRI
Laura Hercher on the DTC Genetic Testing Landscape
Arcadia Biosciences Pivots to Bring Us Non-GMO, High Fiber GoodWheat and Better Cannabis
April 2019 Review with Nathan and Laura: uBiome Raided by FBI, PRS for Obesity, and a Gene Therapy Cure
The Era of the Social Genome with Rodrigo Martinez, Veritas Genetics
Reassessing Alzheimer’s with Larry Goldstein, UCSD
Family Surprises Care of the Home DNA Test with Brianne Kirkpatrick
March 2019 with Nathan and Laura: Old Envelopes, Wooly Mammoth DNA, and the Night King
Single Cell Analysis Shows Important New Detail in Key Clinical Study of AML: Koichi Takahashi, MD Anderson
Science Communication in a Post Fact World with Erik Clausen
February 2019 Review with Nathan and Laura: Family Surprises, IQ Profiling, and Chinese Surveillance
Heretic No Longer? Meet Michael Joyner, Precision Medicine’s Critic-in-Chief
The Internet of Biology Revolution-For Real This Time, with Brett Goldsmith, Cardea
January 2019 Review with Nathan and Laura: Cloning, CRISPRing, DTC, and Paleogenomic Overreach
Cara O'Neill of the Cure Sanfilippo Foundation Tells Her Story
PregSource: The NIH’s Crowdsourcing Project for Pregnancy Data with Caroline Signore
Meet Christian, Janos, and the New World of 3D Oncology
Has Computational Modeling for Cancer Genomics "Arrived?" with Shirley Liu, Dana Farber
Amy Harmon of the NYT on Race & Genetics, Women in Science
CRISPR or Not, You Can't Genetically Enhance Humans, Says Sci-Fi Author Kim Stanley Robinson
The New World of Infectious Disease Diagnosis: Out in the Field with David Hong of Karius
California Life Science Industry Steps to New Heights - the 2019 Edition with Sara Radcliffe
Nathan and Laura on CRISPRed Babies and Other November 2018 Stories
Ellen Matloff on a New Digital Genetic Counseling Product for DTC Customers
Connecting the Dots for a Community of Rare Disease Patients: Terri Klein, MPS Society
Keith Robison and Shawn Baker on Illumina Buyout of PacBio
October 2018 Review with Nathan and Laura: ASHG Does Race, Parents Do Gene Therapy, Unsung Demons
A Point-of-Care CBC Test Based on a Few Drops of Blood—Is This the Real Thing? with Danny Levner, Sight Diagnostics
It’s a Gold Rush in Single Cell Genomics, Says Joachim Schultze, U of Bonn
A Market Solution for Biospecimen Quality Standards with Matt McLoughlin, Scientist.com
September 2018 with Nathan and Laura: Studying the Same Genes and the Matt Fender Story
Single Cell Sequencing Tailor Made for Nephrology, Says Vivek Bhalla, Stanford
It’s the Social Factors, Stupid! Lisa Suennen on Healthcare, Her Career, Digital Health Investing, and . . . Just Being Herself
Concerned About DTC Test Quality? Ask Two Questions, Says Daryl Pritchard, PMC
August 2018 Review with Nathan and Laura: The polygenic month
An International Perspective on How to Improve Biobanking with Kirstin Goldring
A Seqster Preview with Founder Ardy Arianpour
Detective Stories from the Genomic War Room with Ramesh Hariharan
Should Biobanking Come Under CLIA? Shannon McCall, Duke
Pharma Stepping Up, Footing the Bill for Genetic Testing & Counseling: Jordanna Mora, Alnylam
Are We Asking Too Much of Genomics in Cancer Research? Tony Letai, Dana Farber
I Won’t Rest Until We Have Quality Standards in Place for Biospecimens: Carolyn Compton, ASU
May 2018 with Nathan and Laura: The Free Exome, California Database, and Mosaicism
Has Diagnostic Testing Plateaued? Alka Chaubey, Greenwood Genetic Center
A New Way for DTC? Nathan Pearson, Root Deep Insight
Genetic Testing in the Age of Trump: Hank Greely, Stanford
Genetic Testing is Dead, Long Live Genetic Testing: Sean George of Invitae
April 2018 with Nathan and Laura: Golden State Killer and the Cancer Prediction Space
Liquid Biopsy for Infectious Disease with Mickey Kertesz, Karius
Nanopore Sequencing and the Future of Cancer Research with Chia-Lin Wei, JAX
A New Method for Long Reads: Hanlee Ji of Stanford on Cancer Genomics Tech 2018
March 2018 in Genomics with Nathan & Laura: DTC BRCA and Revisiting All of Us
With More Tools in the Box, Lon Cardon Says We’re in a New Age of Drug Development
Personalized Medicine in the Trump Era with Edward Abrahams
Eric Schadt and Sema4 Try the Consumer Model with Newborn Screening Panel
February 2018 in Genomics with Nathan & Laura: 23andMe Goes for the Gold, Trump Year One
State of Sequencing 2018 with Keith Robison, Omics! Omics! Blogger
Direct RNA-Seq Project Shows Nanopore Sequencing Can Reveal New Insights into Basic Biology: Winston Timp, JHU
January 2018 Review Show with Nathan and Laura: CRISPR vs The Immune System, Biotech Math, and MinION's Big Test
Going Beyond the Liver with RNAi: Chris Anzalone of Arrowhead Pharma
Vice Chancellor Keith Yamamoto on UCSF’s Role in Medicine Today
The Global Business of Reproductive Genetic Testing with Gary Harton, Igenomix
The State of Genomics 2018 with Nathan, Laura, and Misha
Sharon Begley of STAT News
A New “Middle Way” for Genomics, with Physical Chemist, Yuval Ebenstein
Sara Demy on Biotech CEOs
November 2017 with Nathan and Laura: The Stem Cell Story We’ve All Been Waiting For and a Sea Change for DTC Testing
Seattle Startup Takes Precision Oncology to the Next Step: Carla Grandori, CEO, SEngine
Immuno Oncology 2017: Looking Back, Looking Forward with Rachel Laing and Olivier Lesueur
Huh? 30 Million Americans Have a Rare Disease? Howard Jacob on the State of Clinical Sequencing
With their Own Manufacturing Facility, Seattle Children’s Goes Big into CAR-T, Rare Disease
With Immuno Oncology Comes a New Focus on Rare Cells
We've Become Too Single Variant Centric, Says Deanna Church on Genome Analysis
Clinicians Show High Demand for Single Cell Sequencing, Says Bobby Sebra of Mt. Sinai
September 2017 with Nathan and Laura: Venter Blunder, RNAi Returns, and Monthly Science Moments
Charting the Dark Matter of Cancer Genomes with Jim Broach
Why Childhood Cancers Need Their Own Gene Panel: Tim Triche
Exploring the Exome and the Future of Genomics with Jay Shendure
August 2017 Review with Nathan and Laura: CAR-T Cashes In, Embryos Edited in US, and the Invitae Incident
The First In-Human Gene Editing Trial in the U.S. - And It’s Not with CRISPR
Thermo, Pfizer, and Novartis Pull Off a First for NGS in Lung Cancer
Making Genetic Testing Mainstream Medicine with Sean George, Invitae
Need Better Standards for Your Clinical Assays? NIST Can Help
Turning on Your DNA with Justin Kao, Helix
Will This New Nano Technology Be the Microarray of Genomic Structural Variation? Barrett Bready, Nabsys
George Church on What Comes After CRISPR
Is CRISPR Controversy Science or Spin? June 2017 Review with Nathan and Laura
We Need a Google Maps for Metagenomics, Says Rob Knight, UCSD
Move Over PDL1: New Test Combo Adds RNAseq to Better Track Immune Escape
The Last Major Disease To Be Studied? Ron Davis of Stanford Thinks So
On Bioinformatics Data Sharing and Collaboration: Andrew Carroll, DNAnexus
Grail Merger, Genomic Autopsies, Overtreatment Alarm, and Controversy at Ancestry.com: May 2017 Review with Nathan and Laura
Is Population Medicine Failing Us? Michel Accad
Deep Omics Profiler, Mike Snyder, Now Turns to Wearables
Over $1 Billion Invested this Past Year: Synthetic Biology in 2017 with John Cumbers
Green Light for DTC, Blood Mammograms, and Ancient DNA: April 2017 with Nathan and Laura
With 50 Million Users, Is Academia.edu Speeding Up Science?
How to Improve Lab Tests in the Absence of FDA Regulation?
Known for Medical Devices, 116 Yr Old BD Makes a Bold Move in Genomics
Proposed NIH Cuts, Undermining GINA, and Game Changing Drugs: March 2017 with Nathan and Laura
Art in the Lab (Falling in Love with Bacteria)
Flint Whistleblower Says Today's Science Is to Blame for Its Own Lack of Public Trust
The Story of Geisinger and Doing Genomic Medicine at the Right Pace
In-Situ Sequencing, CRISPR Patents, and Racist Milk Drinkers: February 2017 with Nathan and Laura
New Pocket Size Nanopore Device Could Revolutionize Diagnostic and Other Testing
By Changing a Basic Lab Step, Acoustic Liquid Transfer Having a Broad Impact
Many Biologists Today Don’t Have Enough Computer Science to Use the Databases
Cardiologists Love Genomics: Euan Ashley, Stanford
Scientists vs Trump: January 2017 with Nathan and Laura
Want to Stop Smoking? Start with Epigenetic Biomarker that Tells Doc the Truth
When an Exome Test Is Part of the Therapy and Not a Diagnostic: John West on Personalis and Personalized Cancer Vaccines
People Told Us It Was Impossible: UCSC’s Mark Akeson on Nanopore Sequencing
When Long Reads are Double the Price of Short Reads, Short Reads Are Dead, Says Evan Eichler
Genomics in 2016: Nathan and Laura Name Their Top Stories
Hank Greely on “The End of Sex" and Other Stuff
How to Scale Cancer Genomics, with Marco Marra, UBC
What Does the Election Mean for Genomics? November 2016 with Nathan and Laura
The Saga Continues: Ethan Perlstein, Indie Scientist, Part 3
Biomarker Panel to Predict Type 1 Diabetes
Can You Name the World’s Largest Single Disease Research Charity?
Why Diversity Is the Only Path Forward: Sarah Tishkoff on African Genomics
October 2016 with Nathan and Laura
We’re Over Halfway There: Baylor's Richard Gibbs on Clinical Genetics
With FDA Guidance on LDTs Still Not Out, What Are Labs Doing?
Reference Genome Making Major Strides in Ethnic Diversity, Says Valerie Schneider, NCBI
September 2016 with Nathan and Laura
Luke Timmerman on His New Biography of Lee Hood
How Personalized is Personalized Medicine? Krister Wennerberg on FIMM’s Individualized Systems Medicine
Digital PCR Opens Up New Liquid Biopsy Opportunity in Melanoma Treatment: David Polsky, NYU
Erica Ramos on Her Pioneering Role as Genetic Counselor for Industry
August 2016 with Nathan and Laura
A Maniacal Commitment to Science: Peering into Regeneron’s Genetics Center with Jeff Reid
The Days of Miracle and Wonder: Laura Hercher on Genetic Counseling, Part 2
The Days of Miracle and Wonder: Laura Hercher on Genetic Counseling, Part 1
A Precision Medicine Platform Comes of Age: Jonathan Hirsch, Syapse
FDA’s Liz Mansfield on New NGS Guidances
How Is the Brexit Impacting Genomics? with Clare Turnbull and Hadyn Parry
It’s Not Really Bulls and Bears: John Carroll on His New Gig, the Brexit, and a New Metaphor for the Market
June 2016 with Nathan and Laura: GMO Labeling, Misspelling CRISPR, Sequenom Patent Loss, SmidgIon
Know Then Thyself: Kari Stefansson, deCODE genetics
Sequenom Patent Loss a Threat to Personalized Medicine, Says Kevin Noonan
Bringing Home Some Diagnostics Gold: Brad Gray, NanoString Show How It’s Done
Mukherjee Mess-up, the Secret Harvard Meeting, and Success in Gene Therapy: May 2016 with Nathan and Laura
When Do We Move to Population Based Cancer Screening for Those with High Genetic Risk? Josh Schiffman, U of U
The Solid Future of Liquid Biopsies with Michael Nall, Biocept
Genomics Is Oversubscribed, Says Creator of BLAST
With 10K Genomes Sequenced, Genomics England in High Gear: Clare Turnbull, Clinical Lead
April 2016 with Nathan and Laura: Big Money, More CRISPR Studies, Genomic Superheroes, and a Pot Chaser
A Sneak Peek into the Future of Clinical Genomics with Ben Solomon, Inova
Preprints and the Future of Science Publishing with Jason Hoyt, PeerJ
Flipping Drug Development Upside Down: Niven Narain, BERG Health
March 2016 with Nathan and Laura: Genomic Jenga and the Creator, the Anti-Abortion Lobby and Genetic Testing, and Theranos, Again
Medicine and the Limits of Science with Michel Accad, MD
How Good are Linked Reads? Serge Saxonov, 10X Genomics
A Home Run on the First Hit: PacBio’s Jonas Korlach
Digital Pathology at Scale: Epic Sciences Takes CTC Technology to the Next Level
February 2016: Mosquitos, Preprints, and that Rocking White House Summit
BioNano Genomics Stakes Out Sequencing Territory as They Discover Lots of De Novo Variants in Reference Genome Projects
Is Oxitec Ready to Scale as Governments Seek Options to Control the Zika Virus?
Human Genome Turns 15: Mike Hunkapiller
January 2016: Landergate, Grail, and Cancer Moonshot
Frontiers of Sequencing: Putting Long Reads and Graph Assemblies to Work
Why Drugs Are Priced So High and Diagnostics So Low
Who Is John Ioannidis?
Cancer: Year in Review 2015 with Anna Barker
Sci-Fi Author Kim Stanley Robinson Talks Life Science 2015
Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler
Genomics and the Cloud Going Through “a Second Puberty,” says AWS’ Angel Pizarro
Hot Biotech Market Neglects Stem Cell Therapies, Says CIRM's Neil Littman
The Future of Diagnostics Reimbursement with Bruce Quinn
Framingham for the Modern Era: Josie Briggs on the Precision Medicine Initiative
Do Alternate Proposals to Regulate LDTs Stand a Chance?
Does the Reproducibility Project in Cancer Biology Offer a Model for a New Kind of Science Auditing?
After CMS Announcement, Peter Maag and CareDx Fight for Life
The Goal Is De Novo Assembly in the Clinic, Says Jim Lupski, Baylor
Cliff Reid Says New Supersequencer Leads the Pack for High Throughput Clinical Sequencing
Defending the Value of Biotech Innovation in California: Sara Radcliffe, CLSA
Long Read Sequencing Dramatically Improves Blood Matching: Steven Marsh, Anthony Nolan Institute
The World of DIY Genomics with K T Pickard
Sequencing in Space: Chris Mason, Cornell
Is the Future of Biology a Return to Chemistry? Carolyn Bertozzi, Stanford
Going Beyond the $1,000 Genome with Mark Gerstein
Creating the Foundation of Genomics: Marc Salit, NIST
Still Unhappy with FDA’s Plan to Regulate LDTs, Professional Lab Groups Go Direct to the Senate
A Diagnostic Success Story with Alka Chaubey, Greenwood Genetic Center
With Two New Easy-to-Use Sequencing Instruments, Thermo Readies for Primetime in the Clinic
Here's Looking at Euclid
Is This the Future of Clinical Trials for Cancer? Stanley Hamilton on the NCI’s New MATCH Trial
Brian Kennedy and Aubrey de Grey on their Converging Approaches to Aging Research
The Business of Aging and Three Reasons Why the FDA Drug Approval Rate Is So High
New York Genome Center’s Nathan Pearson on Public Outreach for Genomics
Tim Triche on Using Arrays for Cancer Research
Thermo’s Chris Linthwaite on Sequencing the Ebola Virus and the Future of Public Health
A Tool to Strengthen the Voice of Science in Online Journalism
Father of Child with Rare Disease Says Science Equals Medicine
Bina CEO Details Secret to Success in NGS Informatics
Cancer Researcher Tim Triche on the Staying Power of Microarrays
Want Answers? Look to the Non-Coding Region of the Genome, Says Cancer Researcher, Tim Triche
Ivan Oransky on Today's Retraction Boom
Genomics-Palooza, Diagnostics Fraud, and Biblical Prophets on the Future of Biotech
Ethical Issues around Editing Human Germline for the Future. Today It's about Plants and Animals, Says NYU's Art Caplan
We Got Research, PCSK9 Inhibitors, and Clinical Trials for Religion
The Multi-Platform Approach to Clinical Sequencing with Bobby Sebra, Icahn School
So That Happened, The Mad Genius, and Selling SynBio
Summer Genomics Festival, the Other Sports Genes, and Brain Surgery for Fruit Flies
The Sports Genes with Jeremy Koenig, Athletigen
Woodstock for Genomics? Richard Lumb and Carl Smith on this Month’s Festival
Geneticists Anonymous, the Sad State of Science Journalism, and New Kids on the Helix
The 9 Billion People Problem: Rod Wing on Plant Genomics
Should We Hold Back the Reins on Biotechnology? with Chris Gunter
Are We Ready to Trust Liquid Biopsies? with Milena Cankovic, Henry Ford Hospital
Gene and Tonic: Boxing for Cancer, Dubious Correlations, and When Should a Researcher Retire
New Patient Focused Genome Magazine Signing up Many Doctors Too
Gene and Tonic: The Decline of Pseudoscience, An Atheist for President, and What to Do with a Sexist Reviewer
Gene and Tonic: Sexism in Science, How to Spend an NIH Budget Increase, How Not to Spend It
Participation in Genomics Research a 21st Century Public Good, Says Paul Billings of Omicia
Gene and Tonic: Competition for 23andMe, Four Tips for Attending AACR 2015, and "Swab Stories"
Improving the Backbone of Clinical Genomics : Valerie Schneider, NCBI
Gene and Tonic: The ACA Turns Five, Ten Reasons to Have Your Genome Sequenced, and Humbled by the Ancients
Behind the Sequencing Bench with Dale Yuzuki
Gene and Tonic: The Tenth Commandment of Science, Icelandic Treasure, and TechBio Babies
It’s Pretty Bad: Andy Brooks of RUCDR on Sample Quality
Knowing More about What We Don’t Know: John McPherson on Cancer Genomics
Gene and Tonic: The iWatch and Research Kit, 23andMe Goes for the Big Time, No Spaceship
In Partnership with IBM’s Watson, Pathway Genomics Reinvents Itself
Affymetrix CEO, Frank Witney, on Arrays in the Age of Sequencing
Gene & Tonic: Disruption in Sequencing, Scientist Politicians, Some Cool Synbio
Changing the World with Color Changing Flowers
Cancer Researcher at Mayo Says Illumina Platform Maxing Out, Looks to BGI/Complete
Returning to Old Biotech Model, OncoMed Boasts of Seven Drugs in Clinical Trials by Mid 2015
Cutting through the Hype in Healthcare Innovation with David Shaywitz and Lisa Suennen
A Call to Consumers to Lead the Shift in Healthcare: Sharon Terry, Genetic Alliance
In Autoimmune Disease, Finding Clarity Beyond the Genome: Stefan Muellner, Protagen
Myriad Settlements Mark End of an Era: Antoinette Konski on Gene Patents
David Schwartz on the Future of Sequencing
Not a Stenographer to Power: Luke Timmerman and the New 'Timmerman Report'
FDA Will Take Time to Digest Comments on LDT Guidance, Says Liz Mansfield
Future of Personalized Medicine at Stake, says Amy Miller of PMC about LDT Regulation
'A Good Year' with John LaMattina
An Exciting Time for Mass Spec: Paul Beresford, Biodesix
Current Version of LDT Draft Guidance Means Much Fewer and Lower Quality Tests for Patients, Says Elaine Lyon of ARUP
The Sad State of Biospecimen Science with David Rimm, Yale
Cancer 2014: The Year in Review with Anna Barker
Faces of Leadership in Diagnostics: Surbhi Sarna
Historic Consensus Reached on Biospecimen Standards: Carolyn Compton, NBDA
Setting Better Expectations for Genomic Medicine: Geoff Ginsburg, Duke University
Test Driving Genomic Medicine: Thomas Quertermous, Stanford
The Silicon Valley Fantasy Trip: Sci-fi Author Kim Stanley Robinson Talks Life Science
Faces of Leadership in Diagnostics: Mara Aspinall
The Daunting Task of Managing Biospecimens at the World's Largest CRO: Diane Farhi, Quintiles
Janet Woodcock, FDA, on Biomarker Development and the Future of Clinical Trials
Biosampling Basics with Scott Jewell, Van Andel Institute
Faces of Leadership in Diagnostics: Bonnie Anderson, Veracyte
Biotech’s Gentleman Lawyer: Alan Mendelson
The Open Secret about the HER2 Assay with Jim Vaught
What a Physicist Can Tell Us about Cancer
'Moving Target Science:' Jonathan Brody on Pancreatic Cancer
The Progress of Clinical Genomics in Sweden with Ulf Gyllensten
Proteins Are Where It's At: Chip Petricoin, George Mason University
After a Decade on the Sidelines, Gene Myers Back into Sequencing, Excited about Long Reads
The Story of Aubrey de Grey and How the Study of Aging Became Mainstream
#ScienceHack with Connor Dickie, Synbiota
What Translational Gap? Michael Pishvaian on Advances in Tumor Profiling
A Dangerous Book? Science Historian Nathaniel Comfort Discusses “A Troublesome Inheritance”
Eric Schadt on Long Read Sequencing and Clinical Genomics
George Church at 60
Major Sequencing Projects Should Be Done with Long Reads, Says Dan Geraghty
Test Driving Illumina's X Ten with Shawn Baker, AllSeq
Short Read Sequencing Not Up to the Task of Characterizing Transcriptome Says Mike Snyder of Stanford
U.K. Life Science Update with Eliot Forster, MedCity
Paperwork, Not Algorithms the Biggest Challenge for Large Bioinformatics Projects, Says David Haussler, UCSC
Big Pharma Does Some Farming: Pearl Huang, GSK